Startup profile · funding coverage
OpenEvidence funding, valuation and investors
AI medical search and clinical decision support with citation-linked evidence for U.S. physicians.
Keep track of OpenEvidence
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$210M · July 15, 2025
Latest known valuation
$3.5B
Series B · July 15, 2025
Total disclosed equity funding
$285M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Cambridge, Massachusetts, USA
Investors in latest funding
Lead: Google Ventures , Kleiner Perkins
Other: Sequoia , Coatue , Thrive Capital , Andreessen Horowitz
Overview
OpenEvidence provides an AI-powered medical search engine and chat interface exclusively for verified U.S. clinicians. It synthesizes peer-reviewed literature and trusted medical sources into citation-linked answers for point-of-care decisions. Founded in 2022 by Daniel Nadler — who sold Kensho to S&P Global for $700M in 2018 — OpenEvidence raised a $75M Series A led by Sequoia in early 2025 at ~$1B valuation, then a $210M Series B in July 2025 at $3.5B co-led by Google Ventures and Kleiner Perkins. a16z, Coatue, Thrive Capital, and Greycroft are among other backers. The company reports 400K+ verified physicians and strong word-of-mouth growth.
Why OpenEvidence is interesting
Kensho founder Daniel Nadler built the fastest-growing physician app since 2022 — $210M Series B (Jul 2025) at $3.5B from GV and Kleiner after Sequoia-led Series A, with 40% of U.S. doctors using it daily per company claims.
Product & use cases
OpenEvidence aggregates medical journals and clinical guidelines into an AI interface that answers physician questions with linked citations. Products include DeepConsult research agents. Free for verified U.S. doctors; monetization via partnerships and enterprise expansions per press.
- Point-of-care evidence lookup during patient visits
- Deep literature review for complex cases via AI research agents
- Staying current on guidelines without manual journal search
- Hospital system deployments for clinical decision support
Key facts
- Series B (Jul 2025): $210M at $3.5B; GV and Kleiner co-led — PR Newswire, Fierce Healthcare
- Series A (Feb 2025): $75M led by Sequoia at ~$1B — MobiHealthNews
- Founder Daniel Nadler sold Kensho to S&P Global for $700M (2018)
- Company claims 40% of U.S. physicians use product daily (Jul 2025 press)
- Co-investors not in VCT directory: Google Ventures, Conviction, DST Global
Funding history (newest first)
Series B
2025-07-15 $210M Valuation: $3.5BSeries A
2025-02 $75M Valuation: ~$1BSource: https://www.mobihealthnews.com/news/openevidence-raises-210m-expand-partnerships-hits-35b-valuation
Investors in our directory
Funds linked from OpenEvidence's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Physician-only verified access builds trust; Nadler's Kensho track record and Sequoia/GV/Kleiner syndicate signal quality bar. Citation-linked outputs address hallucination concerns vs generic ChatGPT.
Clinical AI winners need trust, liability-aware outputs, and EHR-adjacent workflows. OpenEvidence went direct-to-physician with consumer-grade growth loops — rare in healthtech. Incumbents (UpToDate, Epocrates) will add AI features; OpenEvidence's race is to become default evidence layer before hospital procurement consolidates vendors.
-
UpToDate (Wolters Kluwer) incumbent
Gold-standard clinical reference subscribed by hospitals for decades; slower AI-native UX.
-
Google / generic LLMs adjacent
Physicians may use ChatGPT; OpenEvidence differentiates with medical corpus, citations, and verification.
-
Glass Health / other AI scribes adjacent
AI clinical documentation and differential diagnosis tools; overlapping physician AI budget.
-
PubMed / manual search alternative
Free but slow; OpenEvidence automates synthesis with attribution.
Notable stories
- GV backed Nadler at Kensho during his Harvard PhD — OpenEvidence reunites the same investor-founder pair a decade later, per Fierce Healthcare (Jul 2025).
- Nadler named to TIME100 Health list in 2025 as OpenEvidence scaled from founding (2022) to multi-billion valuation in under three years.
Industries
FAQs about OpenEvidence
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.